Today: 7 February 2026
Subscribe

Marcin Frąckiewicz

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

Rare Interstellar Comet 3I/ATLAS – a 10-Billion-Year-Old Time Capsule – Flies Past Mars

Rare Interstellar Comet 3I/ATLAS – a 10-Billion-Year-Old Time Capsule – Flies Past Mars

A Visitor from Beyond the Solar System Humanity has waited a long time to study a comet from another star – and suddenly, within a decade, we’ve had three. 3I/ATLAS (officially 3I/2025 A1) is the latest of these rare interstellar interlopers. It was first detected moving through the outer Solar System in June 2025 with an exceptionally eccentric orbit. Follow-up observations quickly confirmed what its speed and trajectory implied: this object was not bound to the Sun’s gravityts2.tech. By July 2025, the Minor Planet Center designated it the third interstellar object ever foundts2.tech. Like its predecessors – the cigar-shaped 1I/‘Oumuamua and cometary 2I/Borisov – 3I/ATLAS is
8 October 2025
·
Google’s Pixel 10 Pro Fold Shakes Up the Smartphone Wars with AI Tricks, Durability & Bold Design

Google’s Pixel 10 Pro Fold Shakes Up the Smartphone Wars with AI Tricks, Durability & Bold Design

Pixel 10 Pro Fold: Google’s AI-Powered Foldable Flagship Google’s new Pixel 10 Pro Fold is the star of its 2025 lineup – a device that blends cutting-edge hardware with Google’s latest AI software. This foldable phone is branded as the “Pro Fold” variant of the Pixel 10 family, emphasizing that it shares the same core specs and AI features as the Pixel 10 Pro slab phonests2.tech. When closed, it looks like a typical premium smartphone with a 6.4″ OLED display; opened up, it reveals a spacious 8″ tablet-like screen – slightly larger than its predecessor and rival Galaxy foldsts2.tech. The design retains
8 October 2025
···
Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Stock Performance: The 2025 Rollercoaster Ride Xenetic’s stock was relatively quiet for most of 2025 until early October, when it suddenly erupted. By Oct 8, 2025, XBIO had skyrocketed to levels not seen in years. On that day alone, the stock soared 123% to $9.58 (from a prior $4.29 close)finanzen.ch, after touching intraday highs well above $10. This move extended a remarkable run from under $3.50 at the start of the week to nearly $12-13 intraday on Oct 8ainvest.com. In fact, at one point XBIO was up about +195% in a single session according to real-time trackerstimothysykes.com. Such gains are extraordinary – even by penny stock standards
8 October 2025
·
Plant-Based Food Stock Goes Crypto: Above Food (ABVE) Skyrockets in 2025

Plant-Based Food Stock Goes Crypto: Above Food (ABVE) Skyrockets in 2025

Above Food Ingredients Inc. is a Canadian plant-based food tech company that went public via SPAC merger in 2024 Stocktwits. In 2025, its stock ABVE has been on a wild ride – climbing from penny-stock levels to over $4, an almost 8-fold increase in under a year Marketbeat. This meteoric rise comes as Above Food pivots beyond organic grains into gold-backed cryptocurrencies and next-gen financial tech, capturing investor imagination. Below, we dive into Above Food’s mission, business model, financials, stock performance, forecasts, expert commentary, strategic moves, ESG profile, and the latest news driving this micro-cap’s buzz. Company Background and Mission Founded in Regina, Saskatchewan, in 2023, Above Food began with a
8 October 2025
··
Cipher Mining (CIFR) Stock Skyrockets on AI Pivot & Bitcoin Boom – Next Crypto Powerhouse?

Cipher Mining (CIFR) Stock Skyrockets on AI Pivot & Bitcoin Boom – Next Crypto Powerhouse?

Company Overview: Operations & Business Model Cipher Mining Inc. is a pure-play Bitcoin miner operating industrial-scale data centers with a focus on ultra-low-cost powerts2.tech. The company strategically locates its facilities in regions with cheap, renewable-rich electricity (e.g. West Texas), often building behind-the-meter or adjacent to wind and solar farmsts2.techts2.tech. Its flagship “Black Pearl” site near Odessa, TX is a 150 MW facility designed for both Bitcoin mining and high-performance computing (HPC) workloadsts2.tech. As of mid-2025, Cipher’s deployed hashrate reached about 16.8 EH/s (exahashes per second), using next-gen ASIC machines for high energy efficiencyts2.tech. The company had aggressively expanded capacity – a 2.6 GW development pipeline of power projects positions Cipher for further growthts2.tech.
8 October 2025
··
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 Biospace; ~16 patients treated in launch year Nasdaq. Sold to US WorldMeds (2025) Adaptimmune Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase II completed (42% response rate) Stocktitan; FDA Breakthroughdesignation in 2025 Stocktitan; BLA filing planned for 2025. Sold to US WorldMeds (2025) Adaptimmune Uzatresegene (uza-cel, next-gen TCR) Solid tumors (MAGE-A4 TCR, partnered with Galapagos) Preclinical/IND-enabling stage; partnership deal $665M signed 2024 Fiercebiotech. Sold to US WorldMeds (2025) Adaptimmune PRAME-targeted TCR Multiple cancers (PRAME antigen) Preclinical (IND-enabling on hold to cut costs) Biospace. Retained by Adaptimmune Adaptimmune CD70-targeted TCR Hematologic malignancies
8 October 2025
·
Snowflake Stock Soars on AI Boom – Inside SNOW’s 2025 Rally and What’s Next

Snowflake Stock Soars on AI Boom – Inside SNOW’s 2025 Rally and What’s Next

Below, we dive deeper into each of these areas – from Snowflake’s business model and financials to the latest news, analyst insights, competitive dynamics, and what to expect going forward. Company Overview and Business Model Snowflake Inc. is a cloud data platform provider, offering data warehousing as a service alongside a suite of data analytics and sharing capabilities. Unlike traditional databases tied to a single cloud or on-premises, Snowflake’s platform is cloud-agnostic – it runs across Amazon AWS, Microsoft Azure, and Google Cloud, allowing customers to unify their data in one system regardless of cloud providermarkets.chroniclejournal.com. This flexibility has been a major selling point
8 October 2025
··
CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

Sources: Official company reports and press releases; Yahoo Finance and Zacks Investment Research; Reuters and CNBC interviews; TS2 Tech stock analysis and cybersecurity newsts2.technasdaq.commarkets.financialcontent.commarketbeat.comts2.techsiliconangle.comts2.tech. These provide the latest financial data, expert commentary, and industry context as of October 8, 2025.
8 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus Day holiday), the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior sessionstockinvest.us. Technical analysts at Stockinvest.us noted the shares were near the upper part of a wide falling trend and predicted a possible trading range of $26.40–$28.73 on Oct 8, with longer‑term support around $26 and resistance near $31stockinvest.us. While short‑term signals were positive, they cautioned that the overall downward trend remainsstockinvest.us. Because multiple financial
8 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 % at 36 monthsglobenewswire.com. Patients also showed clinical improvements or stabilization of neuropathy and cardiac markersglobenewswire.com, and safety findings were mostly mild infusion‑related eventsglobenewswire.com. CEO John Leonard said the data “demonstrate rapid, deep and durable TTR reductions with meaningful clinical improvements” and reiterated
8 October 2025
··
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote was 3.1 million sharesindmoney.com. Fintel’s data as of 7 Oct 2025 list a market cap of roughly $6.2 billion, a beta of 1.32 and a short interest of 26.3 %, suggesting significant volatility and short‑seller interestfintel.io. The average one‑year price target of $81.3 implies modest
8 October 2025
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis (ATTR)
8 October 2025
··
TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

Overview: TSMC’s Business and Recent Performance Taiwan Semiconductor Manufacturing Co. (TSMC) is the world’s largest contract chipmaker (pure-play foundry), producing advanced semiconductors for clients like Apple, NVIDIA, AMD, and many otherstaiwannews.com.twts2.tech. Rather than selling its own branded chips, TSMC builds chips to order, focusing on cutting-edge manufacturing processes. This model has made TSMC a pillar of global tech supply chains and given it an estimated 60%+ market share of the overall foundry market (and over 90% share in the most advanced nodes)ts2.tech. Financially, TSMC has been on a strong growth trajectory. In Q2 2025, TSMC’s revenue reached US$30.1 billion, a 44%year-on-year surge, with net profit of T$398.3 billion, driven by
8 October 2025
··
Apple Stock Hits New Heights: iPhone 17 Supercycle, Analyst Split, and 2025 Outlook Revealed

Apple Stock Hits New Heights: iPhone 17 Supercycle, Analyst Split, and 2025 Outlook Revealed

Overview: Apple Inc. and Recent Performance Apple Inc. – the world’s largest company by market capitalization – has had a mixed 2025 so far. With a market cap around $3.8 trillionts2.tech, Apple’s size means even modest growth is hard-fought. Year-to-date, AAPL stock is roughly flat (+~2%), underperforming the broader tech sectorts2.tech. This muted performance comes despite Apple achieving record financial results in 2025 (its June quarter revenue jumped ~10% YoY to $94 billion)ts2.tech. Early in the year the stock sold off amid market rotation and AI hype elsewhere, at one point down ~17%. But a strong rebound in late summer – fueled by booming iPhone sales –
8 October 2025
··
Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s Business Model & Market Position Cisco Systems is best known as the world’s largest vendor of networking hardware and software, powering much of the internet’s infrastructure. The company’s business model centers on selling network equipment (like routers, switches, and wireless access points), along with security solutions, collaboration tools (e.g. Webex conferencing gear/software), and observability software (monitoring and analytics, bolstered by its 2024 acquisition of Splunk). In addition, Cisco provides a range of services – from technical support and maintenance contracts to cloud-managed software subscriptions. Cisco generates revenue both through direct sales and via a global channel of resellers and distributors, ensuring its products reach enterprises of all sizes and governments worldwidenasdaq.com. This
8 October 2025
·
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

Current Stock Price and Performance (Oct 8 2025) UnitedHealth Group’s share price has been volatile in 2025. On 8 Oct 2025 the stock closed around $372—IndMoney quoted $372.93 while Investing.com listed $372.64indmoney.cominvesting.com. Reuters reported that the last trade was $371.46, up 2.15 % from the previous dayreuters.com. The wide 52‑week range ($234.60‑$630.73) highlights the enormous drawdown from April’s peak and underscores the severity of the 2025 sell‑off. The stock’s average daily trading volume is about 5.9 million shares, and its beta of 0.47 indicates less volatility than the S&P 500reuters.commarketbeat.com. Year‑to‑date performance remains negative (‑28 % to ‑37 % depending on the reference period), but shares have rebounded more
8 October 2025
Reddit’s Stock Explodes! 78% Revenue Surge, Google AI Deal Talks & 70% Rally 🔥

Reddit’s Rollercoaster: How Booming Ads, AI Deals and Political Scrutiny Could Shock RDDT Investors

Key Facts (as of 8 Oct 2025) Item Detail Sources Current stock price Reddit’s Class A shares traded around $199.54 at 11:58 AM EDT on 8 Oct 2025 with an intraday high of $206.22 and low of $195.01; the official investor‑relations site notes a 52‑week high of $282.95 and low of $69.30investor.redditinc.com. Reddit investor relations Analyst consensus Across 25‑28 analysts the consensus rating is “moderate/buy”. Average price targets range from $200–$223, with highs around $300 (JMP Securities, Oppenheimer) and lows near $75marketbeat.combenzinga.com. MarketBeat, Stockanalysis, Benzinga Q2 2025 results Reddit delivered its first profitable quarter: revenue rose 78 % to $500 M and advertising revenue jumped 84 % to $465 Minvestor.redditinc.com. Adjusted net
8 October 2025
·
Palo Alto Networks’ AI-Fueled Surge: Stock Soars on Cybersecurity Boom, Bold Forecasts & Big Deals

Palo Alto Networks’ AI-Fueled Surge: Stock Soars on Cybersecurity Boom, Bold Forecasts & Big Deals

Sources: Palo Alto Networks and CyberArk deal coverage – Reutersreuters.comreuters.com; Q4 2025 earnings and guidance – Reutersreuters.com, Futurumfuturumgroup.comfuturumgroup.com; Analyst ratings and price targets – StockAnalysisstockanalysis.comstockanalysis.com; Competitive landscape – Bullish Bearsbullishbears.combullishbears.com; Unit 42 threat intel news – ts2.techts2.tech; Expert quotes – Reutersreuters.com, Breakingviewsreuters.com; Stock performance data – Yahoo/Benzingahotcandlestick.com.
8 October 2025
··
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Unraveling Confluent (CFLT) Stock: Latest Price, AI‑Driven Buzz & What Experts Say

Current Stock Price & Recent Performance (as of 8 Oct 2025) Date Open High Low Close Daily Change Notes 8 Oct 2025 $23.72 $24.07 $21.98 $22.84 −10.18 % Stock decline amid deal speculation and market volatilitystockanalysis.com. 7 Oct 2025 $21.33 $21.33 $20.12 $20.73 −2.50 % Day after Reuters’ sale‑rumor report; shares closed near weekly lowstockanalysis.com. 6 Oct 2025 $20.50 $21.49 $20.23 $21.26 +7.36 % Stock rallied following takeover rumorsinvestors.confluent.io. Confluent’s closing price on 8 Oct 2025 was around $22.84stockanalysis.com. INDmoney’s summary for the week lists a closing price of $20.74 and a day’s high of $21.33indmoney.com; the difference likely reflects after‑hours moves or data update timing. The stock trades well below its 52‑week
8 October 2025
·
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Introduction: A New Kind of Biotech Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is redefining drug discovery by combining cutting-edge biology and data science. Based in Salt Lake City, this “TechBio” pioneer uses automation, massive datasets and machine learning to identify new therapies faster than traditional labsdirectorstalkinterviews.comnasdaq.com. Its mission – “to decode biology to radically improve lives” – has attracted major industry partners and bold investors. But as an early-stage biotech with no approved drugs, Recursion’s stock can be a rollercoaster ride, swayed by scientific milestones and market sentiment alike. In early October 2025, Recursion’s stock made headlines after a sudden surge
8 October 2025
···
1 … 240 241 242 243 244 … 352

Stock Market Today

Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

7 February 2026
Coca-Cola will discontinue its frozen products, including the Minute Maid frozen line, in the U.S. and Canada in Q1 2026. Shares closed Friday up 0.66% at $79.03 ahead of Tuesday’s quarterly results. CEO James Quincey sold 337,824 shares on Feb. 3 for about $26 million under a pre-arranged plan. Options pricing suggests a possible 3% move after earnings.
Cisco stock jumps 3% into earnings week as tech shakeout keeps CSCO in focus

Cisco stock jumps 3% into earnings week as tech shakeout keeps CSCO in focus

7 February 2026
Cisco shares closed up 3% at $84.82 Friday after a volatile week for tech stocks. The company will report quarterly results Feb. 11, with analysts expecting EPS of $1.02 on $15.12 billion revenue. U.S. jobs and inflation data, delayed by the federal shutdown, are also due next week. About 23.9 million Cisco shares traded Friday.
Go toTop